DRIVERS OF TREATMENT PREFERENCES IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) PATIENTS: QUALITATIVE INTERVIEWS TO INFORM A PATIENT-PREFERENCE STUDY

被引：0
|
作者：
Mason, B. [1 ]
Eccleston, A. [2 ]
Gater, A. [1 ]
Hauber, B. [3 ]
Thompson, A. [3 ]
Coulter, J. [4 ]
Guy, M. [1 ]
Nunes, Ayala L. [1 ]
Brinkmann, J. [5 ]
Hallworth, P. [6 ]
Cappelleri, J. [7 ]
Bell, B. [6 ]
Chang, J. [3 ]
Satkunasivam, R. [8 ]
机构：
[1] Adelphi Values Ltd, Bollington, Cheshire, England
[2] Pfizer, Tadworth, England
[3] Pfizer, New York, NY USA
[4] Pfizer Inc, Grand Rapids, MI USA
[5] Pfizer Pharma GmbH, Berlin, Germany
[6] Adelphi Res, Bollington, Cheshire, England
[7] Pfizer Inc, New York, NY USA
[8] Houston Methodist Hosp, Houston, TX USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR235
引用
收藏
页码：S494 / S495
页数：2
相关论文
共 50 条
  • [31] Secondary Prevention of non-muscle invasive Bladder Cancer (NMIBC): Randomized Phase 2 Trial of Erdafitinib versus intravesical Chemotherapy of investigator's Choice in Patients with High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) and Recurrence and post FGFR Mutations or Fusions Immunotherapy with Bacillus Calmette-Guerin (BCG) (THOR-2) - AB 78/21 of the AUO
    Rexer, Heidrun
    Kramer, Mario
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2022, 53 (04) : 314 - 315
  • [32] Association of BCG shortage with bladder cancer recurrence in high-risk non-muscle invasive bladder cancer
    Lee, Sangmin
    Lim, Bumjin
    You, Dalsan
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Kim, Choung-Soo
    Jeong, In Gab
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 26 - 27
  • [33] The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)
    Nicolazzo, Chiara
    Busetto, Gian Maria
    Del Giudice, Francesco
    Sperduti, Isabella
    Giannarelli, Diana
    Gradilone, Angela
    Gazzaniga, Paola
    de Berardinis, Ettore
    Raimondi, Cristina
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (10) : 1971 - 1976
  • [34] Biomedical markers of response to intravesical BCG treatment in high-risk non-muscle invasive bladder cancer
    Jallad, S.
    Thomas, P.
    Newport, M.
    Kern, F.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 66 - 67
  • [35] THE LONG-TERM PROGNOSTIC VALUE OF SURVIVIN EXPRESSING CIRCULATING TUMOR CELLS IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Busetto, Gian Maria
    Del Giudice, Francesco
    Gazzaniga, Paola
    De Berardinis, Ettore
    JOURNAL OF UROLOGY, 2018, 199 (04): : E774 - E774
  • [36] The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)
    Chiara Nicolazzo
    Gian Maria Busetto
    Francesco Del Giudice
    Isabella Sperduti
    Diana Giannarelli
    Angela Gradilone
    Paola Gazzaniga
    Ettore de Berardinis
    Cristina Raimondi
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1971 - 1976
  • [37] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Werntz, Ryan P.
    Adamic, Brittany
    Steinberg, Gary D.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2031 - 2040
  • [38] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Ryan P. Werntz
    Brittany Adamic
    Gary D. Steinberg
    World Journal of Urology, 2019, 37 : 2031 - 2040
  • [39] Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer
    Diamant, Elliott
    Roumiguie, Mathieu
    Ingels, Alexandre
    Parra, Jerome
    Vordos, Dimitri
    Bajeot, Anne-Sophie
    Chartier-Kastler, Emmanuel
    Soulie, Michel
    de la Taille, Alexandre
    Roupret, Morgan
    Seisen, Thomas
    CANCERS, 2022, 14 (15)
  • [40] Combination Therapy for Patients with High-Risk non-muscle-invasive Bladder Cancer (HR-NMIBC) Randomized Phase III verum-controlled clinical Trial for Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Patients with High-Risk non-muscle-invasive Bladder Cancer (HR-NMIBC) that persists or relapses following Induction Therapy with BCG (KEYNOTE-676) - AB 64/18 of the AUO
    Rexer, H.
    Ohlmann, C-H.
    Grimm, M-O.
    UROLOGE, 2019, 58 (08): : 991 - 992
12345